Felbamate

CHEMBL1094 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
238.2 g/mol
LogP
0.6
Phase
4

This anticonvulsant works through multiple mechanisms including blocking NMDA receptors and sodium channels to control seizures, particularly in patients with severe, treatment-resistant epilepsy such as Lennox-Gastaut syndrome. It is reserved for severe cases due to the risk of serious side effects.

Berat Molekul

238,2400 g/mol

LogP

0,60

TPSA

105,00 Ų

Lipinski RO5

Lulus

Area Terapeutik

Mekanisme Kerja

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NC(=O)OCC(COC(N)=O)c1ccccc1

InChI

InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)

Molecular Formula

C11H14N2O4

HBD / HBA

2 / 4

Ikatan yang Dapat Dirotasi

7

Atom Berat

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This anticonvulsant works through multiple mechanisms including blocking NMDA receptors and sodium channels to control seizures, particularly in patients with severe, treatment-resistant epilepsy such as Lennox-Gastaut syndrome. It is reserved for severe cases due to the risk of serious side effects.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Felbamate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1094. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3331. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.